Literature DB >> 34431504

Functional interrogation and therapeutic targeting of protein tyrosine phosphatases.

Aaron D Krabill1, Zhong-Yin Zhang1.   

Abstract

Protein tyrosine phosphatases (PTPs) counteract the enzymatic activity of protein tyrosine kinases to modulate levels of both normal and disease-associated protein tyrosine phosphorylation. Aberrant activity of PTPs has been linked to the progression of many disease states, yet no PTP inhibitors are currently clinically available. PTPs are without a doubt a difficult drug target. Despite this, many selective, potent, and bioavailable PTP inhibitors have been described, suggesting PTPs should once again be looked at as viable therapeutic targets. Herein, we summarize recently discovered PTP inhibitors and their use in the functional interrogation of PTPs in disease states. In addition, an overview of the therapeutic targeting of PTPs is described using SHP2 as a representative target.
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  chemical biology; drug discovery; protein tyrosine phosphatase

Mesh:

Substances:

Year:  2021        PMID: 34431504      PMCID: PMC8527391          DOI: 10.1042/BST20201308

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  79 in total

Review 1.  Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction.

Authors:  Nicholas K Tonks
Journal:  FEBS J       Date:  2013-01-17       Impact factor: 5.542

2.  Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.

Authors:  John S Lazo; Isabella K Blanco; Nikhil R Tasker; Ettore J Rastelli; James C Burnett; Sharon R Garrott; Duncan J Hart; Rebecca L McCloud; Ku-Lung Hsu; Peter Wipf; Elizabeth R Sharlow
Journal:  J Pharmacol Exp Ther       Date:  2019-10-10       Impact factor: 4.030

3.  Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.

Authors:  Sanjay K Pandey; Xing Xian Yu; Lynnetta M Watts; M Dodson Michael; Kyle W Sloop; Amber R Rivard; Thomas A Leedom; Vara Prasad Manchem; Laura Samadzadeh; Robert A McKay; Brett P Monia; Sanjay Bhanot
Journal:  J Biol Chem       Date:  2007-03-12       Impact factor: 5.157

Review 4.  Targeting Tyrosine Phosphatases: Time to End the Stigma.

Authors:  Stephanie M Stanford; Nunzio Bottini
Journal:  Trends Pharmacol Sci       Date:  2017-04-12       Impact factor: 14.819

Review 5.  The roles of MAPKs in disease.

Authors:  Michael C Lawrence; Arif Jivan; Chunli Shao; Lingling Duan; Daryl Goad; Elma Zaganjor; Jihan Osborne; Kathleen McGlynn; Steve Stippec; Svetlana Earnest; Wei Chen; Melanie H Cobb
Journal:  Cell Res       Date:  2008-04       Impact factor: 25.617

6.  Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.

Authors:  Jorge Garcia Fortanet; Christine Hiu-Tung Chen; Ying-Nan P Chen; Zhouliang Chen; Zhan Deng; Brant Firestone; Peter Fekkes; Michelle Fodor; Pascal D Fortin; Cary Fridrich; Denise Grunenfelder; Samuel Ho; Zhao B Kang; Rajesh Karki; Mitsunori Kato; Nick Keen; Laura R LaBonte; Jay Larrow; Francois Lenoir; Gang Liu; Shumei Liu; Franco Lombardo; Dyuti Majumdar; Matthew J Meyer; Mark Palermo; Lawrence Perez; Minying Pu; Timothy Ramsey; William R Sellers; Michael D Shultz; Travis Stams; Christopher Towler; Ping Wang; Sarah L Williams; Ji-Hu Zhang; Matthew J LaMarche
Journal:  J Med Chem       Date:  2016-07-12       Impact factor: 7.446

7.  Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer.

Authors:  Tingting Ren; Beihai Jiang; Xiaofang Xing; Bin Dong; Lirong Peng; Lin Meng; Huiyu Xu; Chengchao Shou
Journal:  Pathol Oncol Res       Date:  2009-02-27       Impact factor: 3.201

8.  Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.

Authors:  I Radke; M Götte; C Kersting; B Mattsson; L Kiesel; P Wülfing
Journal:  Br J Cancer       Date:  2006-07-11       Impact factor: 7.640

9.  Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.

Authors:  Gabrielle S Wong; Jin Zhou; Jie Bin Liu; Zhong Wu; Xinsen Xu; Tianxia Li; David Xu; Steven E Schumacher; Jens Puschhof; James McFarland; Charles Zou; Austin Dulak; Les Henderson; Peng Xu; Emily O'Day; Rachel Rendak; Wei-Li Liao; Fabiola Cecchi; Todd Hembrough; Sarit Schwartz; Christopher Szeto; Anil K Rustgi; Kwok-Kin Wong; J Alan Diehl; Karin Jensen; Francesco Graziano; Annamaria Ruzzo; Shaunt Fereshetian; Philipp Mertins; Steven A Carr; Rameen Beroukhim; Kenichi Nakamura; Eiji Oki; Masayuki Watanabe; Hideo Baba; Yu Imamura; Daniel Catenacci; Adam J Bass
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

10.  Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.

Authors:  Clare F Vickers; Ana P G Silva; Ajanta Chakraborty; Paulina Fernandez; Natalia Kurepina; Charis Saville; Yandi Naranjo; Miquel Pons; Laura S Schnettger; Maximiliano G Gutierrez; Steven Park; Barry N Kreiswith; David S Perlin; Eric J Thomas; Jennifer S Cavet; Lydia Tabernero
Journal:  J Med Chem       Date:  2018-09-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.